



Final Appraisal Recommendation

Ranolazine (Ranexa[®]▼)

Re-submission by:
A Menarini Pharma UK SRL

Advice No: 1710 – December 2010

Recommendation of AWMSG

Ranolazine (Ranexa[®]▼) as an add-on therapy is recommended as an option for restricted use within NHS Wales for the symptomatic treatment of patients with stable angina pectoris. Treatment should be initiated by a Cardiologist.

Ranolazine (Ranexa[®]▼) should be restricted for use in patients who remain symptomatic despite treatment with all other pharmacological anti-anginal therapies and where revascularisation has been considered and undertaken or is not considered appropriate.

Additional notes:

Initiation should be supported by appropriate drug-related safety information to ensure the continued safe prescribing of ranolazine (Ranexa[®]▼).

This recommendation replaces AWMSG Advice No. 1909 – December 2009.

In reaching this recommendation AWMSG took account of the AWMSG Secretariat Assessment Report, the preliminary recommendation (PAR) and the applicant company's response to the PAR, clinical expert opinion, lay/patient/carer perspective and discussions at AWMSG.

Statement of use: No part of this recommendation may be used without the whole of the advice being quoted in full and should be cited as: